Abstract: Novel monoclonal antibodies to an aflatoxin B.sub.1 and G.sub.1 in a test kit and used in a method of testing are described. The method for producing the monoclonal antibodies uses repeated administration of aflatoxin B.sub.1 or the related analog compound as a 1-position polypeptide to a murine and production of a hybridoma to generate the novel monoclonal antibodies. The novel antibodies have limited cross-reactivity to aflatoxins B.sub.2, G.sub.2 and M.sub.1. Aflatoxin B.sub.1 or aflatoxin G.sub.1 are detected in foods and the like using the test kit and method.

Abstract: Competitive immunoassays, which employ idiotypic and antiidiotypic monoclonal antibody reagents, are described. These competitive immunoassays are particularly useful for the detection of low concentrations of analyte for which labeled reference analyte is difficult to obtain in quantity. Antiidiotypic monoclonal antibody reagents serves as a substitute for the labeled reference analyte. The antiidiotypic monoclonal antibody reagent exhibits a congruency of structure with one or more epitopes of the analyte or antigen. The antiidiotypic monoclonal antibody is prepared against an idiotypic monoclonal antibody, which, in turn, was prepared against the antigen or analyte. During the immunoassay, the antiidiotypic monoclonal antibody is allowed to compete with the antigen, whose concentration is being determined, for a limited number of antibody binding sites present on an idiotypic antibody, which was also prepared against the antigen or analyte.

Abstract: Methods of determining the ratio of apolipoprotein B-100 to apolipoprotein A-I using ELISA techniques in conjunction with monoclonal paratopic molecules are disclosed as are diagnostic systems useful in performing those determinations. Monoclonal paratopic molecules secreted by hybridomas having ATCC accession numbers HB 8742, HB 8746, HB 9200 and HB 9201 are utilized.

Abstract: A diagnostic site-specific imaging reagent in the form of a receptor and an indicating means selectively binds to a specific cell membrane-associated antigen of a blood platelet that is in a stimulated active state but does not substantially bind to a platelet that is in a non-stimulated resting state. In particular, prelabelled monoclonal antibodies and polyclonal antibodies are prepared that bind and image thrombospondin when it is cell membrane-associated on a thrombin-stimulated platelet, thereby providing means for detecting and discriminating between a stimulated active blood platelet and a non-stimulated resting blood platelet.

Abstract: Hybridoma HB 8986 produces a murine monoclonal antibody which recognizes a new determinant expressed in bronchopulmonary carcinomas and A549 cell line derived tumors. Immunoperoxidase staining with the hybridoma on formalin fixed, paraffin embedded tissues shows that it specifically stains both the cytoplasmic and cell surface. The monoclonal antibody has the ability to distinguish preferably bronchopulmonary carcinomas with glandular differentiation from other bronchopulmonary carcinomas. Additionally, the monoclonal antibody may identify adenocarcinomas through the body.

Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: Monoclonal antibodies were discovered which recognize differentiation antigens on melanocytes and melanoma cells at various stages of differentiation. A system of classification based on these antigens is proposed and their use in the diagnosis and treatment of melanoma is given.

Abstract: A highly sensitive and specific monoclonal-immuno-radiometric assay (M-IRMA) for hCG, using monoclonal antibodies (Mabs) directed against a 37-amino acid synthetic polypeptide analogous to the carboxyl terminus (CTP) of beta-hCG. Accordingly, in one embodiment, a method is described for the determination of human chorionic gonadotrThe present invention was made utilizing funds of the United States Government. The U.S. government is therefore granted a royalty-free, non-exclusive, world wide, paid-up license in this invention.

Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on normal human cytotoxic and suppressor T cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: A process for the therapeutic treatment of cancer patients involving stimulation and promotion of the natural immune system (both T cell and NK cell activity) resisting and inhibiting tumorous growth (cancer) as well as resisting infections (viral, bacterial and fungal) by administering an effective dosage (e.g., 0.25 mg per kilogram of body weight to as low as about 10.sup.-14 mg/kg) of an endogenous endorphin (e.g., leucine-enkephalin and methionine-enkephalin).

Abstract: Immunoglobins are purified by adsorption upon an immobilized protein A adsorbent using a buffer having a pH of 7.5 to 10 and containing a combination of monovalent cations and polybasic anions in a concentration of about 0.6M to 1.75M.

Abstract: Experiments designed to define the differences between the 21 oncogene of DNA isolated from human bladder cancer cells and its corresponding proto-oncogene are described herein. By a series of in vitro recombinations, the difference was initially isolated to a 350 kb segment of DNA; sequencing defined the difference as a change in the Gly.sup.12 codon causing the p21 protein of the oncogene to contain valine at a location where the p21 protein of the proto-oncogene contained glycine. Assays for detecting carcinogenesis based on such differences are also described. In one type of assay, a restriction enzyme specific for either the altered or non-altered DNA segment of the genes are employed to detect carcinogenesis. In another type of assay, seralogical reagents, such as antibody specific for either p21 protein expressed from the proto-oncogene or oncogene, or a common site therein, are described.

Abstract: Monoclonal antibodies against autoimmune RNA proteins such as La/SSB, Ro/SSA, nNP, and Sm. These monoclonal antibodies which are produced by a continuous hybridoma cell line, may be used in methods for detecting the presence of selected autoimmune RNA proteins and antibodies against such proteins in biological samples, and may be incorporated into diagnostic test kits for this purpose. The monoclonal antibodies may be applied in methods for screening subjects for systemic lupus erythematosus, subacute cutaneous erythematosus, neonatal lupus, Sjogren's syndrome, complete congential heart block, and other disorders which involve the presence of antibodies against autoimmune RNA proteins.

Abstract: A method for producing monoclonal antibodies to a trichothecene mycotoxin which are used in a test kit and method of testing are described. The method for producing the monoclonal antibodies uses repeated administration, preferably subcutaneously of a trichothecene polypeptide to a murine and production of a hybridoma to generate the monoclonal antibodies. Trichothecenes are detected in foods and the like using the test kit and method.

Abstract: Disclosed are murine-derived hybridoma tumor cell lines and monoclonal anti-thaumatin antibody substances produced by these cell lines. The monoclonal antibody substances may be used alone or in combination in immunological procedures for isolation of thaumatin and for quantitative detection of thaumatin in fluid samples.

Abstract: A monoclonal antibody having specificity to an isozyme of cardiac myosin heavy chain. The monoclonal antibody is useful as a reagent important for biochemical and pathological researches relating to cardiac muscles and diagnosis of myocardial infarction.

Abstract: A monoclonal antibody having specificity for an antigenic determinant of a B-type blood cell. The monoclonal anti-B, produced by a hybridoma cell (the preparation of which is described), affords a defined, specific and cheap blood grouping reagent. The monoclonal antibody is defined by its specificity and functional affinity.

Abstract: The production of neutralizing antibodies for poliovirus, or other enteroviruses, are disclosed herein employing the capsid polypeptide VP1. Vaccines can be produced employing this polypeptide in place of killed or live attenuated virus, and the VP1 polypeptide can be employed in assays in place of whole virions. VP1 polypeptide can be produced by isolating it from live virion or can be produced by cloning cDNA sequences coding for this protein in recombinant cDNA vectors.

Abstract: Disclosed are antibody substances displaying unique, multi-specific immunoreactivities with respect to glycoprotein D of Herpes Simplex Virus types 1 and 2 (HSV gD-1 and gD-2) and structurally related compounds. Illustratively, an IgG Type 2 monoclonal antibody material produced by mouse-mouse hybridoma cell line A.T.C.C. No. HB8606 is capable of in vitro neutralization of HSV-1 and HSV-2 infectivity and of specific immunological reactivity and reversible immunobinding with natrually-occuring and recombinant gD-1 and gD-2 in both native and denatured conformations as well as with proteinaceous materials (produced, e.g., by proteolytic digestion of naturally-occurring materials, by recombinant methods, or by polymerization of amino acids) which comprise a primary structural conformation substantially duplicating part or all of that which is predicted to be extant at residues 266 through 287 of gD-1 and gD-2 [i.e., PELA(or V)PEDPEDSALLEDPV(or A)GTVA(or S)].

Abstract: Methods and procedures are described for the isolation of human progestin receptors and for the use of human progestin receptors as immunogens in producing both monoclonal and polyclonal antibodies. These antibodies are used for the detection of progestin receptors, such as the progesterone receptor both normal and cancerous tissues.

Abstract: Monoclonal antibodies are provided capable of distinguishing DNA-RNA hybrid complexes from single stranded DNA and RNA and double stranded DNA and RNA. The antibodies find particular use in determining the presence of a specific nucleic acid sequence on a solid surface. Single stranded polynucleotide is fixed to a solid (gel) surface and then hybridized with the complementary probe. The hybrid complex specific monoclonal antibody is then added to bind to any hybrid complexes which have formed. By appropriate label, the hybrid complex may be visualized in a variety of ways.

Abstract: A progesterone concentration level test for mammalian body fluids particularly adapted for milk whereby estrus and pregnancy can be determined. The test can be carried out with a kit of several reagents, test tubes and a dip-stick carrying an anti-progesterone monoclonal antibody.

Abstract: The present invention relates to the radioimmuno detection of cancers by detecting tumor associated antigens and comprising the following steps:(i) preparing samples of hybridoma XMMCO-791 as herein described,(ii) separating and purifying the associated antibody produced by XMMCO-791 hybridomas to obtain the IgG2b isotype,(iii) labelling the antibody thus obtained with a radio active label,(iv) preparing composition containing an effective concentration of said labelled antibody(v) administering said antibody composition to a patient and(vi) thereafter screening said patient to detect concentrations of radioactivity thereby indicating a concentration of antibody.Hybridoma cell line XMMCO-791 was deposited with the American Type Culture Collection (A.T.C.C.), Rockville, MD 20852-1776, on Aug. 14, 1986, and given A.T.C.C. Accession No. HB 9173.

Abstract: Hybridomas secreting monoclonal antibody having specificity for and cytolytic against Trichomonas vaginalis are provided. The cytolytic monoclonal antibodies specific for T. vaginalis are useful in detecting the presence of T. vaginalis among a general population of micro-organisms found in a biological sample. Detection of the T. vaginalis is evaluated by observing cell lysis of T. vaginalis after contacting the cultured micro-organisms with the cytolytic monoclonal antibody specific for T. vaginalis. Therapeutic uses of the monoclonal antibody as an immunological anti-microbial reagent for the treatment of T. vaginalis infection are also disclosed.

Abstract: A conjugate of methotrexate to an antibody is prepared by loading methotrexate onto an aminodextran, then specifically conjugating the polymer carrier to the carbohydrate portion of an antitumor antibody, using a reduced Schiff base linkage. The conjugate is useful for tumor targeted therapy.

Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 10% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8Ul myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: Substantially pure, intracellularly produced, soluble recombinant ricin toxin A (RTA) is recovered from transformed cells by disrupting the cell membrane, removing insoluble cell membrane materials from the disruptate, adjusting the pH of the cell membrane material-free solution to 6 to 6.5 and the conductivity to 1.25 to 1.75 millisiemens, passing the adjusted solution through a bed of SP-cellulose cation exchanger, and eluting the substantially pure RTA from the bed.

Abstract: Novel compounds which are capable of binding with enhanced specificity to the mu opioid receptor are disclosed. The compounds are analogs of somatostain and have the formula: ##STR1## wherein X is CONH.sub.2 or CH.sub.2 OH;Y and Z are independently sulfur or CH.sub.2 ;R.sup.1 and R.sup.2, which may be the same or different, are hydrogen, methyl, ethyl, cyclopentamethylene, or a lower alkyl group having five or less carbon atoms;R.sup.3 and R.sup.4, which may be the same or different, are hydrogen, methyl, ethyl, cyclopentamethylene, or a lower alkyl group having five or less carbon atoms, provided, however, that R.sup.1, R.sup.2, R.sup.3, and R.sup.4 may not all be hydrogen;AA.sub.1 is Phe, D-Phe, phenyl-Gly, D-phenyl-Gly, Tyr, D-Tyr, L-1-Naphthylalanine, D-1-Naphthylalanine, or D-Phe(4-Me);AA.sub.2 is Tyr, Phe, Tyr(OMe), Phe(4-Me),Tyr(OEt), or Phe(4-Et); andAA.sub.3 is Lys, Arg, Orn or homo-Arg.

Abstract: The subject invention provides a means for the immunological detection of an entire class of microorganisms in clinical samples. The detection is accomplished by reaction of the clinical sample iwth a class-specific immunological reagent. This reagent is an antiserum either monoclonal or polyclonal in nature, and the detection is based upon reaction of the antiserum with an antigenic determinant which is shared among all members of the detectable class of microorganisms. The presence of the resulting immunological reaction product (e.g. the antigen-antibody complex) may be detected by well-known immunological detection-systems.

Abstract: According to the present invention there is provided an essentially pure protein found in nature in mast cells and in basophiles, which protein is involved in the transfer of calcium into such cells. Such a protein has an isoelectric point of about 3.9 and a MW about 60,000.+-.2,000, and has an amino acid composition as herein defined. There are also provided processes for the preparation of such purified protein. Such protein is of use in blocking histamine release from cells.

Abstract: Monoclonal receptors that immunologically bind to human apolipoprotein A molecules, particularly apo-A-I and apo-A-II, are described as are their methods of use and articles of manufacture containing them.

Abstract: Bifunctional derivatives of a 3-carboxhydrazide of an antineoplastic dimeric indole-dihydroindole alkaloids, useful both in forming conjugates with immunoglobulins and as anti-tumor agents.

Abstract: A non-human, mammalian monoclonal receptor produced and secreted by a hybridoma having the ATCC accession number HB 8568 and methods of preparing and using same, as well as diagnostics utilizing the receptor are disclosed. The monoclonal receptor reacts with cells such as human neuroectodermal tumors having ganglioside GD.sub.2 antigen expressed on their cellular membrane surfaces.

Abstract: This invention discloses a method for separating a highly pure form of bovine lactoferrin from cow's milk and purifying same which comprises preparing an affinity-chromatographic column by fixing a monoclonal antibody against bovine lactoferrin to an insoluble carrier; passing milk or a solution of bovine lactoferrin derived from cow'milk through the affinity-chromatographic column; and then eluting the bovine lactoferrin adsorbed to the affinity-chromatographic column.

Abstract: Chromatographic procedures are individually and jointly applied to the rapid and efficient isolation of biologically active proteins and especially glycoproteins such as recombinant erythropoietin present in the medium of growth of genetically transformed mammalian host cells. Illustratively, recombinant EPO is isolated from culture fluids by reverse phase chromatography employing a C.sub.4 or C.sub.6 column and elution with ethanol. Recombinant erythropoietin may also be purified by anion exchange chromatography employing, e.g., a DEAE resin, with preliminary selective elution of contaminant materials having a lower pKa than erythropoietin from the resin under conditions mitigating against acid activated protease degradation. Practiced serially, the two chromatographic procedures allow for high yields of biologically active recombinant erythropoietin from mammalian cell culture media.

Abstract: An antineoplastic dimeric indole-dihydroindole (vinca) alkaloid carrying a hydrazine succinimide group at C-3, capable of forming conjugates with a diacid at C-4.

Abstract: Immunogenically active fragments of hepatitis B surface antigen, which are a glycoprotein of molecular weight about 28,000 (gp 28) and a protein of molecular weight about 23,000 (p 23), obtained by known methods by treatment of surface antigen with detergent, are prepared in micelle form substantially free from detergent. The micelles are at least as immunogenic as the unfragmented antigen from which they are derived and are useful in the preparation of hepatitis B vaccine. The detergent is removed by layering the detergent containing fragmentation product on an aqueous buffer containing a sucrose gradient and centrifuging the layered buffer when micelles containing both gp 28 and p 23 form and can be recovered in substantially detergent free form from the centrifuged layered buffer.

Abstract: This invention discloses a novel process for the solubilization, purification and characterization of a protein or proteins from insoluble protein aggregates or complexes. The novel process comprises the use of a dissociating step gradient which can be followed by further purification and concentration. Also disclosed are compositions of matter and vaccines comprising one or more proteins purified according to the novel process of this invention.

Abstract: Monoclonal antibodies specific for a protein associated with a lung surfactant complex, decreased levels of which are related to respiratory distress syndrome, are disclosed. The antibodies are useful for prediction and diagnosis of respiratory problems in newborns.

Abstract: Proteinaceous binding compositions are prepared employing hybrid DNA techogy, where the variable region polypeptides of immunoglobulins are substantially reproduced to provide relatively small protein molecules having binding specificity and lacking the undesirable aspects of the heavy regions of immunoglobulins. The compositions find a wide range of use, particularly for physiological purposes for diagnosis and therapy. The binding compositions may be modified by labeling with radioisotopes, fluorescers, and toxins for specific applications in diagnosis or therapy.

Abstract: Monoclonal antibodies having conformation-dependent specificity for native dsDNA, as exemplified by the IgM antibody produced by murine hybridoma ATCC No HB 8329. These antibodies are used to detect DNA duplex formation in DNA hybridization tests.

Abstract: This specification describes a process for separating impurities from an impure mixture containing proinsulin-like material with substantially complete recovery of said proinsulin-like material, which comprises:(1) applying said mixture to a reverse phase macroporous acrylate ester copolymer resin support at a pH of from about 7 to about 10; and(2) eluting said proinsulin-like material from said support with an aqueous eluant having a pH of from about 8 to about 11 and containing from about 10% to about 30% by volume of an organic diluent selected from the group consisting of acetone, acetonitrile, and a combination of acetone and acetonitrile.

Abstract: This specification describes a process for separating impurities from an impure mixture containing growth hormone-like material with substantially complete recovery of said growth hormone-like material, which comprises:(1) applying said mixture to a reverse phase macroporous acrylate ester copolymer resin support at a pH of from about 7 to about 9; and(2) eluting said growth hormone-like material from said support with an aqueous eluant having a pH of from about 7 to about 9 and containing from about 20% to about 80% by volume of an organic diluent selected from the group consisting of acetone, acetonitrile, and a combination of acetone and acetonitrile.